blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1994940

EP1994940 - Therapeutic use of erythropoietin omega [Right-click to bookmark this link]
Former [2008/48]THERAPEUTIC USE OF A RECOMBINANT ERYTHROPOIETIN HAVING HIGH ACTIVITY AND REDUCED SIDE EFFECTS
[2011/40]
StatusNo opposition filed within time limit
Status updated on  08.03.2013
Database last updated on 24.08.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
Baxter Healthcare S.A.
Thurgauerstrasse 130
8152 Glattpark (Opfikon) / CH
[2010/01]
Former [2008/48]For all designated states
Baxter Healthcare SA
Hertistrasse 2
8304 Wallisellen / CH
Inventor(s)01 / Thompson, Lawrence H.
EP Griffin Companies
704 228th Avenue NE
Suite 791
Sammamish Washington 98101 / US
 [2012/18]
Former [2008/48]01 / Thompson, Lawrence H.
EP Griffin Companies 704 228th Avenue NE Suite 791
Sammamish Washington 98101 / US
Representative(s)Bassett, Richard Simon, et al
Potter Clarkson LLP The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
[N/P]
Former [2008/48]Bassett, Richard Simon, et al
Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham
NG1 5DD / GB
Application number, filing date07075711.709.08.2001
[2008/48]
Priority number, dateUS2000063796211.08.2000         Original published format: US 637962
[2008/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1994940
Date:26.11.2008
Language:EN
[2008/48]
Type: B1 Patent specification 
No.:EP1994940
Date:02.05.2012
Language:EN
[2012/18]
Search report(s)(Supplementary) European search report - dispatched on:EP08.10.2008
ClassificationIPC:A61K38/18, A61P25/00, A61P9/00
[2008/48]
CPC:
A61K38/1816 (EP,US); A61K38/22 (KR); A61P1/18 (EP);
A61P13/12 (EP); A61P25/00 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P37/06 (EP);
A61P7/06 (EP); A61P9/00 (EP); A61P9/04 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2008/48]
Extension statesAL06.09.2007
LT06.09.2007
LV06.09.2007
MK06.09.2007
RO06.09.2007
TitleGerman:Therapeutische Verwendung von Erythropoietin omega[2011/40]
English:Therapeutic use of erythropoietin omega[2011/43]
French:Utilisation thérapeutique d'érythropoïétine omega[2011/40]
Former [2008/48]Therapeutische Verwendung von rekombinanten Erythropoietin mit hoher Wirksamkeit und geringen Nebenwirkungen
Former [2008/48]THERAPEUTIC USE OF A RECOMBINANT ERYTHROPOIETIN HAVING HIGH ACTIVITY AND REDUCED SIDE EFFECTS
Former [2008/48]Utilisation thérapeutique d'érythropoïétine recombinante dotée d'un forte activité et d'effets secondaires réduits
Examination procedure06.09.2007Examination requested  [2008/48]
11.12.2007Loss of particular rights, legal effect: Claims
23.01.2008Despatch of communication of loss of particular rights: Claims {1}
11.02.2009Amendment by applicant (claims and/or description)
11.12.2009Despatch of a communication from the examining division (Time limit: M06)
02.06.2010Reply to a communication from the examining division
08.06.2011Despatch of a communication from the examining division (Time limit: M02)
14.07.2011Reply to a communication from the examining division
29.09.2011Communication of intention to grant the patent
03.02.2012Fee for grant paid
03.02.2012Fee for publishing/printing paid
Parent application(s)   TooltipEP01971896.4  / EP1317276
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010971896) is  09.06.2005
Opposition(s)05.02.2013No opposition filed within time limit [2013/15]
Fees paidRenewal fee
06.09.2007Renewal fee patent year 03
06.09.2007Renewal fee patent year 04
06.09.2007Renewal fee patent year 05
06.09.2007Renewal fee patent year 06
06.09.2007Renewal fee patent year 07
25.08.2008Renewal fee patent year 08
25.08.2009Renewal fee patent year 09
25.08.2010Renewal fee patent year 10
25.08.2011Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
TR02.05.2012
GR03.08.2012
IE09.08.2012
LU09.08.2012
ES13.08.2012
CH31.08.2012
LI31.08.2012
MC31.08.2012
PT03.09.2012
[2014/27]
Former [2014/21]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
TR02.05.2012
GR03.08.2012
IE09.08.2012
ES13.08.2012
CH31.08.2012
LI31.08.2012
MC31.08.2012
PT03.09.2012
Former [2013/33]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
IE09.08.2012
ES13.08.2012
CH31.08.2012
LI31.08.2012
MC31.08.2012
PT03.09.2012
Former [2013/22]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
ES13.08.2012
CH31.08.2012
LI31.08.2012
MC31.08.2012
PT03.09.2012
Former [2013/20]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
CH31.08.2012
LI31.08.2012
MC31.08.2012
PT03.09.2012
Former [2013/16]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
MC31.08.2012
PT03.09.2012
Former [2013/11]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
IT02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/08]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
NL02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/07]AT02.05.2012
BE02.05.2012
CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/04]BE02.05.2012
CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2013/01]CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
PT03.09.2012
Former [2012/50]CY02.05.2012
FI02.05.2012
SE02.05.2012
GR03.08.2012
Former [2012/49]CY02.05.2012
FI02.05.2012
SE02.05.2012
Former [2012/48]FI02.05.2012
SE02.05.2012
Documents cited:Search[A]WO8800241  (UNIV WASHINGTON [US]) [A] 1-10 * page 2, line 6 - line 14; claim - *;
 [A]WO0024893  (AMGEN INC [US]) [A] 1-10 * page 4, line 30 - page 7, line 10; claim - *;
 [Y]  - H. LUDWIG, "Epoetin in cancer-related anaemia", NEPHROLOGY DIALYSIS TRANSPLANTATION, (199902), vol. 14, no. suppl 2, pages 85 - 92, XP002219608 [Y] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1093/ndt/14.suppl_2.85
 [Y]  - CAN ERYTHROPOIETIN STUDYGROUP, "ASSOCIATION BETWEEN RECOMBINANT HUMAN ERYTHROPOIETIN AND QUALITY OF LIFE AND EXERCISE CAPACITY OF PATIENTS RECEIVING HEMODIALYSIS", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1990), Database accession no. PREV199089118498, XP002219609 [Y] 1-10 * abstract *
 [PA]  - S. MILUTINOVIC ET AL., "Erythropoietin-induced hypertension in dialyzed uremics is influenced by glycosylation patterns of the molecule.", NEPHROLOGY DIALYIS TRANSPLANTATION, (200106), vol. 16, no. 6, page A91, XP008010133 [PA] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1093/ndt/16.1.1
 [PA]  - S. MILUTINOVIC ET AL., "Differences in glycosylation structures have an important impact on potency and pharmacokinetics of erythropoietin (EPO) in dialyzed uremics.", NEPHROLOGY DIALYSIS TRANSPLANTATION, (200009), vol. 15, no. 9, page A156, XP008010132 [PA] 1-10 * abstract *
    [ ] - BRITISH MEDICAL JOURNAL, (1990), vol. 300, no. 6724, ISSN 0959-8138, pages 573 - 578
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.